Effect of short-term treatment with pravastatin on cytokines and cytokine receptors in patients with chronic heart failure due to ischemic and nonischemic disease.
The antiinflammatory effect of lipoproteins through neutralization of circulating endotoxin has questioned the safety of lipid-lowering drugs in chronic heart failure (CHF). We measured serum levels of interleukin-6, tumor necrosis factor (TNF)-alpha, and soluble TNF-alpha receptors 1 and 2 before and after 1-month treatment with pravastatin 40 mg in 58 patients with CHF. Short-term treatment with pravastatin attenuated the immune response in patients with CHF due to ischemic or nonischemic etiology.
Conraads
Viviane M
VM
Department of Cardiology, University Hospital, Antwerp, Belgium.
Bosmans
Johan M
JM
Schuerwegh
Annemie J
AJ
De Clerck
Luc S
LS
Bridts
Chris H
CH
Wuyts
Floris L
FL
Stevens
Wim J
WJ
Vrints
Christiaan J
CJ
D000368:Aged; D016022:Case-Control Studies; D016207:Cytokines / Q000187:drug effects* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D018836:Inflammation Mediators / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000150:complications* / Q000175:diagnosis; D017035:Pravastatin / Q000008:administration & dosage*; D011336:Probability; D011446:Prospective Studies; D018121:Receptors, Cytokine / Q000187:drug effects* / Q000378:metabolism; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
D016207:Cytokines; D018836:Inflammation Mediators; D018121:Receptors, Cytokine; D017035:Pravastatin